B Cell Lymphoma
Feature
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
But some radiation oncologists do not agree with the proposal to move back to direct in-person supervision only.
Conference Coverage
High Marks for New CAR T Toxicity Grading Tool
A real-world study demonstrates the benefits of a new grading system to assess hematotoxicities across disease types following CAR T-cell...
Feature
New Trials in Leukemia and Lymphoma: Could Your Patient Benefit?
Adults with previously untreated follicular lymphoma or diffuse large B-cell lymphoma may be eligible to participate in one of three randomized,...
Feature
Are Food Emulsifiers Associated With Increased Cancer Risk?
Food emulsifiers are among the most widespread food additives.
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
Conference Coverage
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?
New research suggests that CAR T-cell therapy might prove to be a game-changing treatment for lupus and two other autoimmune diseases.
Conference Coverage
Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T
Awaiting CAR T therapy, patients with complete response to interim chemo show better outcomes with subsequent autologous transplantation, compared...
Conference Coverage
ASH 2023: Equity, Sickle Cell, and Real-Life Outcomes
Leaders of the American Society of Hematology preview hot topics and presentations on tap at their 2023 annual meeting.
News
FDA approves pirtobrutinib for previously treated CLL/SLL
FDA greenlights pirtobrutinib as third-line treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma in adults.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
FDA investigates secondary cancers from CAR T-cell therapies
The agency is evaluating the need for regulatory action on the links between CAR T-cell immunotherapies and secondary blood cancers.